Charles River Laboratories Intl. Inc (NYSE:CRL) Receives Average Recommendation of “Buy” from Analysts

Share on StockTwits

Shares of Charles River Laboratories Intl. Inc (NYSE:CRL) have been assigned a consensus recommendation of “Buy” from the eighteen analysts that are currently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $147.15.

A number of research firms recently weighed in on CRL. Zacks Investment Research lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Svb Leerink initiated coverage on Charles River Laboratories Intl. in a research report on Monday, June 10th. They issued an “outperform” rating and a $155.00 price target for the company. ValuEngine lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Leerink Swann initiated coverage on Charles River Laboratories Intl. in a research report on Monday, June 10th. They set an “outperform” rating for the company. Finally, Evercore ISI restated an “outperform” rating and set a $160.00 price objective on shares of Charles River Laboratories Intl. in a research report on Tuesday, April 30th.

Shares of NYSE:CRL traded down $3.93 during midday trading on Friday, reaching $125.07. The company had a trading volume of 253,387 shares, compared to its average volume of 335,206. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.38 and a current ratio of 1.59. Charles River Laboratories Intl. has a 1-year low of $103.00 and a 1-year high of $149.07. The firm has a market cap of $6.30 billion, a price-to-earnings ratio of 20.74, a price-to-earnings-growth ratio of 1.65 and a beta of 1.10. The company has a fifty day simple moving average of $134.69 and a two-hundred day simple moving average of $136.64.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, July 31st. The medical research company reported $1.63 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.55 by $0.08. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The business had revenue of $657.60 million during the quarter, compared to analyst estimates of $662.61 million. During the same quarter last year, the company posted $1.62 EPS. Charles River Laboratories Intl.’s revenue for the quarter was up 12.4% on a year-over-year basis. Analysts expect that Charles River Laboratories Intl. will post 6.53 EPS for the current year.

In other Charles River Laboratories Intl. news, insider David Ross Smith sold 1,249 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $130.36, for a total transaction of $162,819.64. Following the completion of the sale, the insider now directly owns 19,327 shares in the company, valued at approximately $2,519,467.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William D. Barbo sold 4,905 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $125.16, for a total value of $613,909.80. Following the sale, the insider now owns 25,859 shares of the company’s stock, valued at $3,236,512.44. The disclosure for this sale can be found here. Company insiders own 1.80% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of CRL. Geode Capital Management LLC raised its position in Charles River Laboratories Intl. by 6.7% during the fourth quarter. Geode Capital Management LLC now owns 457,529 shares of the medical research company’s stock worth $51,782,000 after acquiring an additional 28,878 shares during the period. Deutsche Bank AG raised its position in shares of Charles River Laboratories Intl. by 30.7% in the fourth quarter. Deutsche Bank AG now owns 51,182 shares of the medical research company’s stock valued at $5,790,000 after buying an additional 12,024 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Charles River Laboratories Intl. by 21.7% in the first quarter. Nisa Investment Advisors LLC now owns 15,741 shares of the medical research company’s stock valued at $2,286,000 after buying an additional 2,809 shares during the last quarter. Financial Gravity Wealth Inc. acquired a new stake in shares of Charles River Laboratories Intl. in the first quarter valued at about $59,000. Finally, CWM LLC raised its position in shares of Charles River Laboratories Intl. by 156.9% in the first quarter. CWM LLC now owns 429 shares of the medical research company’s stock valued at $62,000 after buying an additional 262 shares during the last quarter. 93.63% of the stock is owned by institutional investors.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: Mutual funds are not immune from market timing

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.